Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
H7N9 LAIV (Research Institute of Influenza)
- Development stage
- Unknown
- Lead developer
- Smorodintsev Research Institute of Influenza
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intranasal
01
Overview
H7N9 LAIV is a monovalent live-attenuated influenza vaccine developed by the Research Institute of Influenza (RII) in Saint Petersburg, Russia, for pandemic preparedness against the H7N9 avian influenza virus. The vaccine candidate, specifically the A/17/Hong Kong/2017/75108 (H7N9) strain, is a reassortant virus produced using the cold-adapted A/Leningrad/134/17/57 (H2N2) master donor strain. It contains the hemagglutinin (HA) and neuraminidase (NA) genes from the A/Hong Kong/125/2017 (H7N9) wild-type virus. Administered intranasally, the vaccine is designed to mimic natural infection and stimulate a broad immune response, including mucosal IgA, systemic IgG, and T-cell mediated immunity, without causing the disease itself.
- Other names
- H7N9 LAIVH-7N9 LAIVH 7N9 LAIVA/17/Hong Kong/2017/75108 (H7N9) LAIVH7N9 live attenuated influenza vaccineH-7N9 live attenuated influenza vaccineH 7N9 live attenuated influenza vaccine
02
Targets
Influenza A virus neuraminidase N9 secondary sialic acid binding siteSA (Sialic acid)
Beyond the preview
Go deeper on H7N9 LAIV (Research Institute of Influenza).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on H7N9 LAIV (Research Institute of Influenza).